Oncology Drug Pipeline Analysis Market – Size, Shares, Trends, Demand, Outlook and Future Forecast Till 2026

1
Oncology Drug Pipeline Analysis Market Size,
Shares, Trends, Demand, Outlook and Future
Forecast Till 2026
The oncology field is witnessing rapid growth,
owing to emergence of novel therapies with high
efficacy, which in turn is boosting growth of the
oncology drug pipeline market. For instance, in
2015, the U.S. Food and Drug Administration (U.S
FDA) approved 45 New Molecular Entity (NME) and
new Biologic License Applications (BLA), of which
16 were novel cancer therapies. Therefore,
developments of novel drugs is a major factor
propelling growth of the global oncology drug
pipeline analysis market. Request Sample Copy of
Research Report https//www.coherentmarketinsigh
ts.com/insight/request-sample/2184 Oncology Drug
Pipeline Analysis Drivers Innovative
approaches in the cancer treatment is a major
factor boosting growth of the oncology pipeline
drugs market. For instance, the novel basket
study includes patients with a certain genetic
mutation in common, regardless of the site or
origin of cancer in the body. Basket studies can
be useful when a drug targets certain genetic
mutation at a particular site and using that drug
to treat same genetic mutation in cancer at
another site. For instance, Larotrectinib, a drug
of Loxo Oncology, Inc., is currently under
review by the U.S. FDA for the treatment of
tyrosine kinase mutation by using basket
studies. This drug has been approved as
Investigational New Drug in May
2018. Combinational therapies are the latest
development driving the growth of oncology
pipeline drugs market. For instance, Pfizer Inc.
is undergoing efficacy and safety study for
Avelumab in combination with chemotherapy,
followed by maintenance therapy of Avelumab with
PARP inhibitor talazoparib in patients with
history of untreated advanced ovarian cancer.
This study is under clinical phase III trials
and is expected to complete in May 2026.
2
Oncology Drug Pipeline Analysis Regional
Analysis On the basis of region, the global
oncology drug pipeline analysis market is
segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate in terms
of growth in oncology drug pipeline market.
According to the 2015 annual report of the
American Cancer Society, although cancer-related
death rate in the U.S. have reduced, cancer
still remains the second most common cause of
death in the country. Therefore, such high
prevalence of cancer is expected to drive growth
of the oncology drug pipeline market in North
America. Key players operating in the global
oncology pipeline drugs market include, F.
Hoffmann-La Roche Ltd., Bristol-Myers Squibb
Company, Johnson Johnson Services, Inc.,
AstraZeneca, Pfizer Inc., AbbVie Inc., Celgene
Corporation, Novartis AG, Merck Co., Inc.,
Sanofi, Eli Lilly Co., GlaxoSmithKline, and
Amgen Inc. Get Best Discount On Research Report
https//www.coherentmarketinsights.com/insight/re
quest-discount/2184 Oncology Drug Pipeline
Analysis Taxonomy By Drug Class Immunotherapy
Monoclonal Antibody Antibody-Drug Conjugate
(ADC) Others By Cancer Type Breast Cancer
Ovarian Cancer Prostate Cancer Lung Cancer
Colorectal Cancer Pancreatic Cancer Others By
Route of Administration Oral Parenteral By
Region North America Europe Asia Pacific Latin
America Middle East Africa For More
Information https//www.coherentmarketinsights.co
m/ongoing-insight/oncology- drug-pipeline-analysi
s-market-2184
3
About Coherent Market Insights Coherent Market
Insights is a prominent market research and
consulting firm offering action-ready syndicated
research reports, custom market analysis,
consulting services, and competitive analysis
through various recommendations related to
emerging market trends, technologies, and
potential absolute dollar opportunity. Contact
Us Mr. Shah Coherent Market Insights 1001 4th
Ave, 3200 Seattle, WA 98154 Tel
1-206-701-6702 Email sales_at_coherentmarketinsight
s.com